secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001437749-25-032184
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed appoints former McKinsey Senior Partner David Quigley to Board
-----------------------------------------------------------------------

- David Quigley appointed to board effective Oct 27, 2025; board expanded from 7 to 8 members.
- Quigley was McKinsey Senior Partner (2010-2025) leading Private Capital and Life Sciences practices.
- Granted option to buy 16,200 shares at $7.02, vesting in 36 equal monthly installments.
- Company expects FDA feedback on Phase 3 trial design for neflamapimod in DLB in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/0001437749-25-032184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/crvo20251029c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-032184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer